X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAN711
Therapeutic Area: Rare Diseases and Disorders Product Name: SAN711
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Data comparing SAN711 to the non-selective GABA-A activator diazepam demonstrated that SAN711 did not induce the sedation seen with diazepam. Saniona expects SAN711 to enter a Phase 1 study in healthy volunteers in mid-2021, with data expected in early 2022.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SAN711
Therapeutic Area: Rare Diseases and Disorders Product Name: SAN711
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
SAN711 was designed using Saniona’s ion channel drug discovery engine to bind with high selectivity to the α3 subunit of the GABAA receptor, which in preclinical models has resulted in efficacy with fewer side effects.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
